Premium
The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status
Author(s) -
Glenjen Nils,
Hovland Randi,
Wergeland Line,
Wendelbo Øystein,
Ernst Peter,
Bruserud Øystein
Publication year - 2003
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1034/j.1600-0609.2003.00130.x
Subject(s) - hepatocyte growth factor , phenotype , cancer research , interleukin 8 , leukemia , biology , cd34 , chronic myelogenous leukemia , karyotype , immunology , cytokine , stem cell , gene , genetics , receptor , chromosome
Introduction: The cytogenetic abnormalities and the response to induction therapy have been regarded as the most important prognostic parameters in acute myelogenous leukemia (AML) patients. Recent studies have demonstrated that internal tandem duplications and specific D‐835 point mutations of the Flt3 gene, as well as the angioregulatory phenotype represent additional adverse prognostic factors. The aim of the study was to investigate possible associations between genetic abnormalities, differentiation status and angioregulatory phenotype in native human AML blasts. Method: Native AML blasts derived from consecutive patients were cultured in vitro and concentrations of angioregulatory molecules determined in the supernatants. Results: Most patients released at least two different angioregulatory mediators. Pro‐angiogenic interleukin 8 (IL8) was released at relatively high levels for most patients, many of these patients showed additional release of pro‐angiogenic vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). High release of anti‐angiogenic IL12 was associated with high release of pro‐angiogenic IL8 and VEGF. Furthermore, patients with D‐835 mutations showed increased IL12 release, whereas patients with normal karyotype had decreased HGF release. Myelomonocytic differentiation was associated with IL18 release and CD34 expression with low IL12 release. Conclusion: Our results suggest that native human AML blasts have a pro‐angiogenic phenotype. Although the investigated genetic abnormalities are associated with variation in the in vitro release of angioregulators, these differences are relatively small and do not quantitatively involve the most important IL8 release. It therefore seems unlikely that this phenotypic variation can explain the prognostic impact of the genetic abnormalities.